The headline is a starting price for a compounded prescription, not a generic version of Wegovy. Its usefulness depends on the clinical reason for compounding and the full terms of the selected care plan.
- Reviewed product
- Compounded semaglutide injection
- Public price boundary
- Advertised from $99/month
- Prescription
- Required; eligibility determined clinically
- Research date
- October 8, 2026
Identify the exact product
CoreAge Rx advertises compounded semaglutide with supplies and shipping and a same-price-at-every-dose claim. The provider’s catalog identifies standard and separate microdose offerings. This review covers the standard weight-management offering, not an experimental low-dose protocol.[source]
What the evidence applies to
A patient comparing price should first distinguish compounded semaglutide from FDA-approved Wegovy. No independent trial of the dispensed CoreAge Rx preparation was verified here. Branded trial results should not be quoted as the expected outcome of this provider’s compounded formulation.[source]
Understand the complete cost
The advertised starting figure needs a billing-term check. Ask whether the quote requires prepaying several months, what consultation fee applies and how much is refundable if the clinician does not approve treatment. Supplies and shipping are provider-advertised inclusions, not independently audited benefits.[source]
Care, refills and practical details
If a clinician recommends treatment, confirm the dispensing pharmacy, concentration, storage instructions and who can answer a dosing question. Compounded vials can create measurement risks. Do not translate a syringe-unit instruction from another product or source into your own directions.[source]
Safety questions come before the price
FDA has identified concerns including dosing errors, inappropriate dose escalation and unapproved salt forms in the compounded GLP-1 market. Obtain treatment through a licensed prescriber and pharmacy, and ask why an approved drug cannot meet the clinical need. These medicines can have serious adverse effects; a low price is not a safety assessment.[source]
Compare a genuinely similar option
Ro’s Wegovy injection option is a branded-product comparison, with a separate care fee. Mochi’s compounded semaglutide is a closer formulation-category comparison, but its starting medicine quote excludes membership and may change with dose. The lowest displayed number does not settle the choice.
Read the full provider review and the total-cost guide before treating any headline as the complete treatment budget.
Your questions, answered
Is the displayed price my guaranteed total?
No. It is the public price boundary recorded on the review date. The prescribed product, dose, membership, billing period and eligibility can change the amount you pay.
Did you buy or test this treatment?
No. This is a source-based product and access review. We did not obtain a prescription, purchase medication or independently test treatment results.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Accessed October 8, 2026.
- CoreAge Rx: current advertised treatments and pricesProvider starting prices; final plan and billing terms require confirmation
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags
- NIDDK: prescription medicines for overweight and obesityEligibility, long-term care, treatment context and insurance questions